OncoMatch/Clinical Trials/NCT06740240
68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
Is NCT06740240 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-FAPI-Biotin and 68Ga-FAPI/18F-FDG for tumor.
Treatment: 68Ga-FAPI-Biotin · 68Ga-FAPI/18F-FDG — As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-Biotin in patients with various types of cancer and compared them with the results of 68Ga-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAPI.
Check if I qualifyEligibility summary
For patients with Tumor.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify